These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 17540858

  • 1. Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model.
    Tamaoki S, Yamauchi Y, Nakano Y, Sakano S, Asagarasu A, Sato M.
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1315-23. PubMed ID: 17540858
    [Abstract] [Full Text] [Related]

  • 2. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A, Matsui T, Hayashi H, Tamaoki S, Yamauchi Y, Minato K, Sato M.
    J Med Chem; 2010 Nov 11; 53(21):7549-63. PubMed ID: 20931963
    [Abstract] [Full Text] [Related]

  • 3. Biotransformation of 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a novel 5-hydroxytryptamine (5-HT)1A agonist/5-HT3 antagonist, in human hepatic cytochrome P450 enzymes.
    Minato K, Suzuki R, Asagarasu A, Matsui T, Sato M.
    Drug Metab Dispos; 2008 May 11; 36(5):831-40. PubMed ID: 18238859
    [Abstract] [Full Text] [Related]

  • 4. The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats.
    Lindström E, Ravnefjord A, Brusberg M, Hjorth S, Larsson H, Martinez V.
    J Pharmacol Exp Ther; 2009 Jun 11; 329(3):1048-55. PubMed ID: 19325032
    [Abstract] [Full Text] [Related]

  • 5. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):190-5. PubMed ID: 17658508
    [Abstract] [Full Text] [Related]

  • 6. Roles of serotonin receptor subtypes for the antinociception of 5-HT in the spinal cord of rats.
    Jeong CY, Choi JI, Yoon MH.
    Eur J Pharmacol; 2004 Oct 19; 502(3):205-11. PubMed ID: 15476746
    [Abstract] [Full Text] [Related]

  • 7. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats.
    Liu FY, Xing GG, Qu XX, Xu IS, Han JS, Wan Y.
    J Pharmacol Exp Ther; 2007 Jun 19; 321(3):1046-53. PubMed ID: 17329553
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May 19; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 9. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
    van den Buuse M, Gogos A.
    J Pharmacol Exp Ther; 2007 Mar 19; 320(3):1224-36. PubMed ID: 17194799
    [Abstract] [Full Text] [Related]

  • 10. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties.
    Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W.
    J Pharmacol Exp Ther; 2005 Sep 19; 314(3):1274-89. PubMed ID: 15951399
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of the 5-hydroxytryptamine (5-HT)1A receptor inverse agonists Rec 27/0224 and Rec 27/0074 on electrophysiological responses to 5-HT1A receptor activation in rat dorsal raphe nucleus and hippocampus in vitro.
    Corradetti R, Mlinar B, Falsini C, Pugliese AM, Cilia A, Destefani C, Testa R.
    J Pharmacol Exp Ther; 2005 Oct 19; 315(1):109-17. PubMed ID: 15951403
    [Abstract] [Full Text] [Related]

  • 12. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC, Dong L, Wang Y, Wang SH, Cao MB.
    Chin Med J (Engl); 2007 Dec 05; 120(23):2069-74. PubMed ID: 18167178
    [Abstract] [Full Text] [Related]

  • 13. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
    Cussac D, Palmier C, Finana F, De Vries L, Tardif S, Léger C, Bernois S, Heusler P.
    J Pharmacol Exp Ther; 2009 Oct 05; 331(1):222-33. PubMed ID: 19605522
    [Abstract] [Full Text] [Related]

  • 14. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist.
    Piper BJ, Vu HL, Safain MG, Oliver AJ, Meyer JS.
    J Pharmacol Exp Ther; 2006 May 05; 317(2):838-49. PubMed ID: 16434566
    [Abstract] [Full Text] [Related]

  • 15. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
    Kawano K, Mori T, Fu L, Ito T, Niisato T, Yoshida S, Shiokawa S, Sato Y, Murakami H, Shishikura T.
    Neurogastroenterol Motil; 2005 Apr 05; 17(2):290-301. PubMed ID: 15787949
    [Abstract] [Full Text] [Related]

  • 16. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC.
    Synapse; 2006 Dec 15; 60(8):599-608. PubMed ID: 17001660
    [Abstract] [Full Text] [Related]

  • 17. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P, Newman-Tancredi A, Loock T, Cussac D.
    Eur J Pharmacol; 2008 Feb 26; 581(1-2):37-46. PubMed ID: 18190908
    [Abstract] [Full Text] [Related]

  • 18. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
    Bellini M, Rappelli L, Blandizzi C, Costa F, Stasi C, Colucci R, Giannaccini G, Marazziti D, Betti L, Baroni S, Mumolo MG, Marchi S, Del Tacca M.
    Am J Gastroenterol; 2003 Dec 26; 98(12):2705-11. PubMed ID: 14687821
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
    Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M.
    Inflammopharmacology; 2007 Feb 26; 15(1):5-9. PubMed ID: 17323187
    [Abstract] [Full Text] [Related]

  • 20. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
    Harada K, Aota M, Inoue T, Matsuda R, Mihara T, Yamaji T, Ishibashi K, Matsuoka N.
    Eur J Pharmacol; 2006 Dec 28; 553(1-3):171-84. PubMed ID: 17074317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.